Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease

  • In News
  • April 28, 2025
  • Gracen Moore
PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease

Australian biotech PYC Therapeutics (ASX:PYC) has taken a major step forward with its lead program, presenting clinical data that signals a significant opportunity in the treatment of genetic eye diseases — a space where no treatments currently exist.

The company announced that interim results from its Phase 1/2 trials for VP-001 — a drug candidate targeting Retinitis Pigmentosa type 11 (RP11) — will be presented at two major international conferences in May.

Showcasing Clinical Success

PYC announced that VP-001 has demonstrated a favourable risk-benefit profile in ongoing open-label Phase 1/2 studies. 

The data reveal that treatment with VP-001 led to statistically significant improvements in vision on registrational endpoints. Specifically, patients showed notable gains in Low Luminance Visual Acuity and microperimetry compared to both their untreated ‘fellow’ eye and the natural history of the disease.

Delivering Clinically Meaningful Improvements

PYC highlighted that these improvements have already translated into meaningful day-to-day benefits for patients.

The company noted that patients who received the therapy experienced clearer central vision and reduced haze. Some even required updated eyeglass prescriptions due to the improvement in their treated eye.

One participant described the moment they first noticed the treatment’s effects: seeing the white lid of a coffee cup for the first time in years. Another reported being able to see airplanes and stars at night — everyday sights that had previously been invisible to them.

Prioritising Safety and Tolerability

Importantly, VP-001 appears to be safe and well-tolerated.

PYC noted that there have been no treatment-related or procedure-related serious adverse events reported in any patient who has received VP-001 to date.

This clean safety profile could set PYC’s proprietary RNA platform apart from other precision medicine approaches for blinding eye diseases, opening up future potential to expand into other indications with significant unmet need.

Accelerating Toward a New Drug Application

Following these promising results, PYC has confirmed a critical next step.

The company will meet with the US Food and Drug Administration (FDA) on 6 June 2025 to align on the design of registrational studies intended to support a New Drug Application (NDA) for VP-001.

PYC added that VP-001 has already received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA — a suite of regulatory advantages aimed at expediting the drug’s pathway to market.

Strengthening Market Position in RNA Therapeutics

PYC’s broader strategy leverages its proprietary drug delivery technology to enhance the potency of RNA therapies, a drug class that has gained significant traction globally.

The company’s focus on monogenic diseases — where a single gene mutation drives the condition — positions it in a high-probability development segment within biotech.

With three clinical-stage programs currently underway, PYC is working to carve out a leadership role in the treatment of severe, previously untreatable genetic disorders.

Preparing for Major Industry Showcases

The new data will be unveiled at two important events: the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit on 2 May 2025, and the Association for Research in Vision and Ophthalmology (ARVO) conference between 4–8 May 2025, both in Salt Lake City, Utah.

If registrational studies proceed successfully, VP-001 could become the first approved treatment for RP11, offering a lifeline to patients who currently face inevitable vision loss.

  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025
  •  
  •  
  •  
  •  
  • ASX:PYC
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    April 28, 2025, 8:15 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/ophthalmic-aav-gene-therapy

    Reply
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Gracen Moore
Latest posts by Gracen Moore (see all)
  • Stakk Secures T-Mobile Contract to Power Super App Expansion - September 30, 2025
  • Medibank Backs Emyria with Landmark Depression Care Deal - September 22, 2025
  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI - September 19, 2025
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.